1353results about "Amine active ingredients" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention discloses a novel application of a small molecule compound BRD4780 in resisting ricin, the small molecule compound BRD4780 has a remarkable effect of resisting ricin toxicity and can be used in development of anti-ricin drugs, a brand new candidate molecule is provided for development of the anti-ricin drugs, the drug research and development blank in the field is filled, and the application of the small molecule compound BRD4780 in resisting ricin is developed. The method has important significance in the aspects of clinical treatment, biological protection and immunotoxin treatment safety optimization, and is wide in application prospect.

Hydrogen-bonded framework nanoparticles comprising a chemiluminescent compound (e.g., L-012) are provided and can be used, e.g., for sono-optogenetic treatment of neurodegenerative diseases such as Parkinson's disease. Related in vivo and therapeutic methods are also provided.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.

The invention relates to the technical field of medical chemistry, in particular to a bridge oxygen site regulatively modified rhodamine anti-cancer fluorescent compound as well as a preparation method and application thereof. The invention develops the rhodamine anti-cancer fluorescent compound of which the meso site is functionalized by tetraarylethene and the bridge oxygen site can be regulated and modified, the fluorescent compound has adjustable red light-near infrared fluorescence emission and excellent fluorescence quantum yield, and the quantum yield can be as high as 99%; the fluorescent compound specifically targets mitochondria, and mainly inhibits growth of tumor cells by inducing para-apoptosis; under irradiation of 655 nm near-infrared laser, ferroptosis is further triggered, efficient treatment of tumor cells is achieved through chemical-photodynamic synergistic effect, and a new treatment thought is provided for overcoming tumor drug resistance.

The invention belongs to the technical field of medicines, and particularly relates to a composition for improving obesity and promoting cardiovascular health as well as a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 5 to 20 parts of glycine betaine, 1 to 5.5 parts of choline chloride, 0.5 to 4 parts of L-theanine, 1 to 15 parts of alpha-ketoglutarate calcium, 0.5 to 3 parts of black ginger extract, 0.05 to 0.25 part of black pepper extract, 0.5 to 3 parts of ginkgo leaf extract and 1 to 6 parts of black garlic juice powder. According to the invention, the eight components are selected and are scientifically combined in an optimal quantity ratio range, and the prepared composition can better reduce the inflammation level of a body, regulate abnormal blood fat, improve the lipid metabolism disorder state and effectively reduce impulsive diet behaviors, so that comprehensive improvement of obesity and cardiovascular related risks is realized, and the health-care effect of a human body is improved. The body is effectively assisted to maintain metabolic health.

The invention belongs to the technical field of drug delivery systems, and discloses a two-dimensional vermiculite-based drug delivery system and a preparation method and application thereof. The preparation method comprises the following steps: carrying out ion exchange on expanded vermiculite, NaCl and LiCl, stripping by using a mechanical stripping sheet, centrifuging to obtain a two-dimensional vermiculite nanosheet dispersion liquid, dispersing a drug in the two-dimensional vermiculite nanosheet dispersion liquid, and forming a film to obtain the two-dimensional vermiculite-based drug delivery unit. The drug is synergistically loaded between layers and on the surface of the vermiculite; rich hydroxyl groups and interlayer cations on the end surface of the vermiculite interact with the drug, so that the drug release time is relatively long; the vermiculite-based drug delivery system can realize gradient order release of drugs according to a sequence from the surface to the interlayer through pH response of an affected part. Meanwhile, the vermiculite-based drug delivery system provides an antibacterial effect through enzyme-like catalytic activity, and avoids the problems of abuse of antibiotics and drug resistance.

A pharmaceutical composition comprising a metal channel activator and a glutamic acid modulator is provided. Also provided is a method of treating depressive disorder comprising administering the pharmaceutical composition. Also provided is a method of treating a neurological or neurodegenerative disorder comprising administering the pharmaceutical composition. Also provided is a method of treating a pain disorder comprising administering the pharmaceutical composition.

The invention discloses application of amantadine in inhibition of ITGAV in preparation of medicines for treating dry age-related macular degeneration, and belongs to the technical field of biological medicines. At present, no report for researching the ITGAV gene in the dry AMD exists, the specific action mechanism is not clear, and amantadine adaptation diseases do not include the dry AMD; according to the application disclosed by the invention, the gene target ITGAV is screened from mutual hair generation of microglial cells and RPE cells in a retina microenvironment, and amantadine is used for inhibiting ITGAV protein to relieve the progress of AMD, so that a new thought is provided for treating dry AMD. Experiments show that amantadine can inhibit ITGAV and delay EMT transformation of RPE cells. In a dry AMD mouse model induced by sodium iodate, RPE cell damage can be remarkably relieved by intraocular injection of amantadine, and the structure and function of a retina layer are improved. These results indicate that it may function in early intervention of dry AMD.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

The present disclosure provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. Salmeterol or a pharmaceutically acceptable salt thereof may be administered conjointly with an erythropoiesis-stimulating agent, optionally wherein the anemia is refractory to the erythropoiesis-stimulating agent. Also provided are methods of promoting differentiation of an erythroid progenitor cell toward a mature red blood cell in a patient in need thereof, comprising administering an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. The present disclosure further provides methods comprising administering salbutamol or a pharmaceutically acceptable salt thereof. Salmeterol, salbutamol, or a pharmaceutically acceptable salt thereof may be administered conjointly with other FDA-approved drugs such as luspatercept, lenalidomide, daprodustat, vadadustat, an erythropoiesis-stimulating agent (ESA), and / or a hypomethylating agent.

The present invention relates to intracellular copper zinc superoxide dismutase inhibitors for protecting a subject from damage caused by radiation outbreak. The invention also relates to kits comprising SOD1 inhibitors and radiosensitizers for cancer cells, to the in vitro use of SOD1 inhibitors for protecting non-cancer cells from ionizing radiation, and to methods, compositions and uses related thereto.

The present disclosure provides, among other things, methods, compositions, and uses for treating diseases or disorders characterized by elevated red blood cells using β2 adrenergic receptor antagonists such as β2-specific adrenergic receptor antagonists (e.g., ICI-118551, butaxamine, or pharmaceutically acceptable salts thereof) or β1 / β2-specific adrenergic receptor antagonists (e.g., propranolol or a pharmaceutically acceptable salt thereof). Also provided are methods, compositions, and uses for decreasing erythroid differentiation using the same. Provided methods of treatment comprise administering an effective amount of a β2-specific adrenergic receptor antagonist or a β1 / β2-specific adrenergic receptor antagonist to a patient in need thereof. Also provided are methods, compositions, and uses for ICI-118551 in treating splenomegaly, splenic erythroid hyperplasia, and / or splenic architecture effacement.

The invention relates to the technical field of intelligent manufacturing, in particular to sterile directly-prepared blowing-filling-sealing-time-throwing-bottle eye washing liquid and a preparation process thereof. The process comprises the following steps: S1, preparing materials; s2, concentrated preparation; s3, diluting and preparing; s4, sterilizing and filtering; and S5, through a BFS sterile filling process, injecting the to-be-filled eyedrops in the liquid storage tank while performing blow molding on the secondary throwing bottle by using sterilized sterile air, and sealing to obtain the secondary throwing bottle eyedrops. The eye washing liquid in the secondary throwing bottle is prepared from directly prepared eye washing liquid materials in a sterile manner; a multi-stage filtration sterilization and storage time threshold early warning discarding process is adopted in the preparation process, so that the sterile condition in the preparation process is ensured; and meanwhile, a BFS sterile filling process is adopted, so that blowing, filling and sealing are integrated, and sterility is realized.

The present invention relates to methods for alleviating symptoms selected from the group consisting of fatigue and frailty associated with aging, skin aging, muscle weakness, statin-associated muscle symptoms, cardiovascular diseases, kidney diseases, and CoQ10 depletion and mitochondrial failure associated with adult neurodegenerative diseases. The present invention further relates to methods for improving mitochondrial function in the end organs.

The disclosed compositions, systems, and methods relate to compositions for human consumption and comprise a combination of paraxanthine and / or 1-methylxanthine and chlorogenic acid, and optionally other compounds that modulate the effect of the combination of paraxanthine and / or 1-methylxanthine and chlorogenic acid. Also disclosed are methods of using the aforementioned compositions to improve at least one of cognitive ability, mood, and / or sleep.

Methods of treating a subject for a dissociative disorder and methods of screening agents for the ability to modulate dissociative and associative states in a subject are provided. In particular, agents that alter rhythmic neural activity in the posteromedial cortex can be used to modulate dissociative and associative states in a subject.

Described herein are pinoxifene compositions comprising novel compounds and methods of use thereof. Methods of synthesizing the compositions are described herein. The odoxifene compositions described herein may exhibit aromatase inhibitory activity or estrogen receptor activity. The odoxifene compositions described herein can be used to treat a condition, such as cancer, in a subject.

The invention discloses a triarylmethane type I photosensitive dye as well as a synthesis method and application thereof. The structure of the dye is shown as a general formula I; intramolecular charge separation is optimized by regulating substituent groups, and the generation efficiency of superoxide anions and hydroxyl radicals is remarkably improved. According to the synthesis method, 4-diphenylaminobenzaldehyde or 4-vinyl benzaldehyde is used as a raw material, efficient preparation is achieved through the steps of condensation, oxidation and the like, the raw material is easy to obtain, and operation is easy and convenient. The dye has strong absorption at the wavelength of 600-630 nm, is suitable for red light triggered photodynamic therapy (PDT), especially keeps high reactive oxygen yield under the hypoxic condition, and breaks through the oxygen dependence limitation of traditional PDT. Experiments show that the dye can induce ferroptosis of tumor cells, has the functions of fluorescence imaging and treatment, and has wide application prospects in the fields of antitumor drugs, in-vivo fluorescence labeling, photoresponsive functional preparations and the like.

To provide antisense oligonucleotide sequences and methods of using the same for treating neurological diseases.SOLUTION: Provided is an oligonucleotide comprising linked nucleosides having a sequence of at least 19 contiguous nucleobases, wherein the sequence of nucleobases comprises a portion of at least 10 contiguous nucleobases that is at least 90% complementary to an equal length portion of nucleobases contained at a specified position of a specified sequence.SELECTED DRAWING: Figure 1A

Title: Composition comprising a particular agent, tocopherol in a specific content and an anionic surfactant and / or an amphoteric or zwitterionic surfactant The present invention relates to a composition comprising: a) at least one agent chosen from acids comprising at least one linear or branched, saturated or unsaturated aliphatic chain containing from 3 to 5 carbon atoms and their salts; b) at least 0.2% by weight of at least one antioxidant agent chosen from tocopherol and its esters relative to the total weight of the composition; and c) at least one surfactant chosen from anionic surfactants, amphoteric or zwitterionic surfactants and their mixtures.

The invention discloses a traditional Chinese medicine composition for treating pruritus vulvae, which is prepared from the following raw material medicines in parts by weight: 200-280 parts of fried fructus xanthii, 100-140 parts of radix sophorae flavescentis, 100-140 parts of cortex phellodendri, 100-140 parts of alum, 100-140 parts of fructus cnidii, 100-140 parts of roasted herba epimedii and 2-6 parts of borneol, and the traditional Chinese medicine composition can effectively treat various pruritus vulvae problems and recover pudendum health.

The invention discloses an ultrasonic response quaternary ammonium salt polymer antibacterial agent and a preparation method thereof. The ultrasonic response quaternary ammonium salt polymer is prepared by the following steps: carrying out substitution reaction on azodiisobutylimidazoline and acryloyl chloride, then carrying out addition polymerization reaction with 4-aminomethylpiperidine, and then carrying out quaternization reaction with bromohexane. The obtained ultrasonic response quaternary ammonium salt polymer can be decomposed under the ultrasonic action to generate alkyl radicals, and has the sterilization effect. In addition, quaternary ammonium salt modification can improve the water solubility and the positive charge density of the polymer, and further improves the antibacterial performance.

The present invention relates to an inhibitor of intracellular copper-zinc-superoxide dismutase for use in protecting a subject from injury by a radiation burst. The present invention also relates to a kit comprising an SOD1 inhibitor and a radiosensitizer of cancer cells, to an in vitro use of an SOD1 inhibitor for protecting non-cancer cells from ionizing radiation, and to methods, compositions, and uses related thereto.

The present invention belongs to the technical field of polymer materials, and specifically relates to a vegetable oil-based carbon dioxide absorbent, its preparation method and antibacterial application. In the present invention, oleic acid chains or epoxidized oleic acid chains are introduced onto the molecules of typical amine absorbent polyethyleneimine. The non-polar long carbon chain fatty acid structure can significantly weaken the hydrogen bonds between polyethyleneimine molecules, reduce the intermolecular force, so that more amino groups are exposed to combine with carbon dioxide, realizing the efficient, high-capacity and low-energy consumption absorption of carbon dioxide. In the present invention, the unsaturated carbon-carbon double bonds on the oleic acid chains are epoxidized and modified, introducing more secondary amines, further improving the carbon dioxide absorption capacity. Moreover, after absorbing carbon dioxide, the tertiary amines in the molecular structure are converted into quaternary ammonium salt ions, endowing it with excellent antibacterial properties, showing excellent antibacterial effects against both Staphylococcus aureus and Escherichia coli, and can be used as an antibacterial agent.

The invention provides a phenoxy (hetero) aryl ether with anti-proliferative activity. The invention of the present application includes novel aromatic molecules useful in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders, such as disorders of the hematopoietic system, including the blood system, in human and veterinary medicine.

The invention provides a novel antibacterial and anti-inflammatory functional additive, a preparation method and application, and belongs to the technical field of biological materials, the additive is organic-inorganic hybrid nanoparticles, and is formed by self-assembly of metal ions, natural polyphenol compounds and quaternary ammonium salt compounds. According to the antibacterial / anti-inflammatory functional additive disclosed by the embodiment of the invention, the antibacterial / anti-inflammatory functional additive has the effects of high biocompatibility, rapid active sterilization, long-acting passive bacteriostasis and inflammation immunity regulation and control.